<DOC>
	<DOCNO>NCT01143753</DOCNO>
	<brief_summary>This open-label , multi-center study evaluate safety , tolerability , pharmacokinetics RO5212054 [ PLX3603 ] participant BRAF V600-mutated advance solid tumor . Cohorts participant receive escalate oral dos RO5212054 . Anticipated time study treatment disease progression unacceptable toxicity occur .</brief_summary>
	<brief_title>A Study RO5212054 ( PLX3603 ) Participants With BRAF V600-Mutated Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Advanced solid tumor Doseescalation phase : Histologically confirm , newly diagnose relapsed/ refractory unresectable American Joint Committee Cancer ( AJCC ) Stage IIIC IV disease Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Adequate liver , renal bone marrow function Participants standard therapy exists consider appropriate investigator Prior treatment inhibitor BRAF ( sorafenib allow ) Active Central nervous system ( CNS ) lesion , history know carcinomatous meningitis Treatment chemotherapy , radiotherapy , immunotherapy investigational agent within 28 day prior first dose study drug Anticipated ongoing anticancer therapy administer study Serious cardiovascular illness within 6 month prior study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>